Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)

NCT07307053 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

600

Enrollment

OTHER

Sponsor class

Conditions

Rare Malignant Neoplasm
Advanced Solid Tumors
Metastatic Solid Tumors

Interventions

DRUG: BL-B01D1
DRUG: VSV injection
DRUG: CVL006
BIOLOGICAL: IDOV-SAFE
BIOLOGICAL: KXV01 TCR Lentinvivo Injection
BIOLOGICAL: MT027
BIOLOGICAL: QH101
BIOLOGICAL: Meta10-TIL
BIOLOGICAL: TAEST1901
BIOLOGICAL: TC-N201
BIOLOGICAL: NK510
DRUG: CE120
DRUG: GV20-0251
DRUG: LYC001
DRUG: YSCH-01
DRUG: BMD006
DRUG: CREPT-618
BIOLOGICAL: PRG2505
DRUG: IBI363
DRUG: YL-201

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences